ST. LOUIS, MO–(Marketwire – August 23, 2010) –  Lickenbrock Technologies (www.lickenbrock.com) announced today the release of its first commercial product, Fundus View™. Fundus View is the first release in the Fundus View family of products, and provides an easy-to-use interface that allows investigators to enhance digital fundus photographs to more clearly visualize retinal features, including the retinal vasculature in both normal and pathological conditions, and other pathological features such as retinal detachments and drusen.

Fundus View can be used to process color images from a standard fundus camera, as well as monochrome for flourescein angiography and indocyanin green (ICG) angiography. Fundus View can also be used to process images from scanning laser ophthalmoscope (SLO) systems as well as other laser-based fundus imagers.

Fundus View is currently an investigational tool, and is not intended to be used as a primary diagnostic tool. The intended user groups include:

• Practitioners that obtain fundus images on a routine basis for documentation purposes. Fundus View can enhance poor quality images so that re-imaging is not necessary.
• Practitioners with research interests that present on a regular basis at meetings. Fundus View can enhance details for clearer visualization for discussion purposes, including patient education.
• Researchers operating in a medical center environment. Fundus View can improve image quality in situations such as Retinopathy of Prematurity (ROP) where it is difficult to obtain high-quality images. Fundus View can also provide enhancement of images to provide ancillary information in clinical research cases. Additionally the FV processing tools can be used for images obtained both in vivo and in vitro in pre-clinical models such as retinal flat mounts.

Fundus View features include:

• Intuitive point and click user interface
• Deconvolution
• Shading correction
• Advanced automated contrast enhancement
• Cup to disc ratio measurement
• View color planes
• Image history

Fundus View is available for purchase via a secure internet connection through the Lickenbrock Technologies website (www.lickenbrock.com) for $295. For additional information contact [email protected].

About Lickenbrock Technologies

Lickenbrock Technologies, located in St. Louis, MO, creates advanced image processing and analysis software for the biomedical industry, with a focus on ophthalmic imaging. Lickenbrock® was founded in 2006. It is a spin-off from AutoQuant Imaging, Inc.® The main business unit of AutoQuant was acquired by Media Cybernetics® in April 2006, and the remaining unsold part of the business dedicated to ophthalmic imaging became Lickenbrock Technologies, LLC.

CHICAGO, IL–(Marketwire – August 23, 2010) –  The National Council of State Boards of Nursing (NCSBN^®) (www.ncsbn.org) met in Portland, Ore., Aug. 11-13, 2010, to consider pertinent association business with its member boards of nursing. All 60 member boards were represented by delegates.

Highlights of some of the significant actions approved by the member boards of nursing included:

• Adopted revisions to the NCSBN Bylaws; 
• Revised the NCSBN Mission Statement;
• Accepted the 2011-2013 Strategic Initiatives;
• Approved the Bermuda Nursing Council, the College of Licensed Practical Nurses of Alberta and the College of Licensed Practical Nurses of British Columbia as associate members of NCSBN; 
• Revised the NCSBN Model Practice Act and Administrative Rules; 
• Adopted the Guiding Principles for Continued Competence;
• Approved the 2011 NCLEX-PN Test Plan; and
• Elected new directors to the Board of Directors and members of the Leadership Succession Committee.

“One of the most important outcomes of this meeting was the delegates’ adoption of a new mission statement for the organization. Delegates embraced the need for an updated and more inclusive mission that focused on regulatory excellence for public protection,” commented newly elected NCSBN President Myra A. Broadway, JD, MS, RN, executive director, Maine State Board of Nursing. She continued, “In addition, I know that the opportunity to network and debate important issues during this meeting will positively influence the work members perform in their jurisdictions in the coming year.”

NCSBN will meet Aug. 2 – 5, 2011, in Indianapolis for its next annual Delegate Assembly.
The National Council of State Boards of Nursing (NCSBN) is a not-for-profit organization whose members include the boards of nursing in the 50 states, the District of Columbia and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are also seven associate members.

Mission: NCSBN provides education, service and research through collaborative leadership to promote regulatory excellence for patient safety and public protection.

The statements and opinions expressed are those of NCSBN and not the individual member state or territorial boards of nursing.

National Council of State Boards of Nursing, Inc.
111 E. Wacker Drive, Suite 2900
Chicago, IL 60601-4277

WAYNE, PA–(Marketwire – August 23, 2010) –  Clinical and Laboratory Standards Institute (CLSI) and Association of Public Health Laboratories (APHL) recently announced the September-December 2010 schedule of educational teleconferences for clinical and public health laboratories. Teleconferences are based on current CLSI documents and are intended to help pathologists, managers, supervisors, technologists, as well as laboratory and quality consultants learn how to optimize practices and processes in their laboratories.

Teleconference speakers are subject matter experts from CLSI subcommittee and working groups involved in creating CLSI documents. “Teleconference programs are a cost effective method to train a large number of laboratory professionals,” said Marcy Anderson, Education Director, CLSI. Participants can gain valuable information from experts in the field and have the opportunity to ask specific questions during the question-and-answer session at the end of the program.

Topics of upcoming teleconferences include:

• Deciding Factor: Selection Criteria for Point-of-Care Testing Devices (588-614-10)
  September 16 • 1:00-2:00 PM Eastern (US) Time

• Ensuring That Hematology Analyzers Tell the Truth (588-615-10)
  September 23 • 1:00-2:00 PM Eastern (US) Time

• POC Glucose Devices: Perspectives From the Hospital, Government, and Vendor (588-623-10)
  September 30 • 1:00-2:30 PM Eastern (US) Time (1.5 contact hours)

• Getting It Right: Approaches to Reducing Errors at the Point of Care (588-616-10)
  October 7 • 1:00-2:00 PM Eastern (US) Time

• First Step to Success: Accurate Patient and Sample Identification (588-617-10)
  October 21 • 1:00-2:00 PM Eastern (US) Time

• Blood Cultures: Current Methods/Future Trends (588-619-10)
  November 4 • 1:00-2:00 PM Eastern (US) Time

• Quality Indicators: Measure to Manage (588-619-10)
  November 18 • 1:00-2:00 PM Eastern (US) Time

• AST for Infrequently Isolated or Fastidious Bacteria (588-620-10)
  December 2 • 1:00-2:00 PM Eastern (US) Time

APHL is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) P.A.C.E.^® Program. Participants will be awarded contact hours for each program they successfully complete. P.A.C.E.^® is accepted by all licensure states except Florida. Florida continuing education credit will also be offered.

CLSI is a volunteer-driven, membership-supported, nonprofit organization dedicated to developing standards and guidelines for the health care and medical testing community through a consensus process that balances the perspectives of industry, government, and the health care professions. For additional information on CLSI, visit the CLSI website at www.clsi.org or call 610.688.0100.

Click here to see all recent news from this company

LEE, MA–(Marketwire – August 23, 2010) –  Wave Systems Corp. (NASDAQ: WAVX) (www.wave.com) today announced that Boston Medical Center’s Network Security Engineer Mark Mulvaney will share his insights on the need for encryption in hospitals and discuss the fundamental differences between software- and hardware-based encryption. Mulvaney will present “Encryption: Hardware or Software? Lessons from the Field,” from 3:00-3:30 p.m. as part of Forrester Security Forum, held Sept. 16-17 at the Westin Copley Place, Boston, Mass.

Boston Medical Center (BMC) is a 639-bed licensed academic medical center located in Boston’s historic South End. Primarily a teaching affiliate for the Boston University School of Medicine, BMC provides a full range of pediatric and adult care services, from primary to family medicine to advanced specialty care. It has the largest 24-hour Level 1 trauma center in New England.

With an increasingly mobile workforce using laptops, BMC took proactive steps to mitigate the possibility of data breach in the event a laptop was lost or stolen. Mulvaney, one of two individuals with primary responsibility for IT security at BMC, advocated replacing the hospital’s existing software encryption with self-encrypting hard drives.

Wave’s EMBASSY® management software provides policy-based access controls, pre-boot authentication and centralized administration for self-encrypting hard drives based on the Trusted Computing Group’s Opal specification. Should a loss or theft of a laptop occur, Wave’s management software enables IT to produce detailed event logs, thereby proving that information on the laptop was encrypted at the time of loss in order to show compliance to the data privacy regulations. See more details at wave.com.

Representatives of the company will demonstrate these capabilities at the Trusted Computing Group’s booth (#208).

This year the focus of the Security Forum is on: evaluating the maturity and effectiveness of the security organization; laying out a road map for architectural optimization and innovation; and ensuring the right skills, incentives and metrics are in place for the long-term success of the security program. The event attracts senior-level IT and information security executives, senior-level practitioners, IT infrastructure and operations professionals, among others.

About Wave Systems Corp.
Wave provides software to help solve critical enterprise PC security challenges such as strong authentication, data protection, network access control and the management of these enterprise functions. Wave is a pioneer in hardware-based PC security and a founding member of the Trusted Computing Group (TCG), a consortium of more than 100 companies that forged open standards for hardware security. Wave’s EMBASSY® line of client- and server-side software leverages and manages the security functions of the TCG’s industry standard hardware security chip, the Trusted Platform Module (TPM) and supports the TCG’s “Opal” self-encrypting drive standard. Self-encrypting drives are a growing segment of the data protection market, offering increased security and better performance than many existing software-based encryption solutions. TPMs are included on an estimated 300 million PCs and are standard equipment on many enterprise-class PCs shipping today. Using TPMs and Wave software, enterprises can substantially and cost-effectively strengthen their current security solutions. For more information about Wave and its solutions, visit http://www.wave.com.

Safe Harbor for Forward-Looking Statements
This press release may contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company’s financing plans; (ii) trends affecting the company’s financial condition or results of operations; (iii) the company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Wave assumes no duty to and does not undertake to update forward-looking statements.

All brands are the property of their respective owners.

DALLAS, TX–(Marketwire – August 23, 2010) – Metiscan, Inc., publicly traded under the ticker symbol (PINKSHEETS: MTIZ), announced today that the Company has filed its Registration Statement on Form S-1 with the Securities and Exchange Commission (SEC).

Bryan A. Scott, President and CEO of Metiscan, Inc., commented, “Our SEC Counsel has advised us that our Registration Statement on Form S-1 was filed with the SEC and that the review and comment period has begun. We look forward to working with the SEC to make our registration effective and to become a fully reporting issuer that is traded on the Over-the-Counter Bulletin Board.”

Interested parties may access MTIZ information from the SEC website at www.SEC.gov.

As previously announced, Metiscan will be hosting a nationwide teleconference on Wednesday, September 1, 2010 at 4:15 PM (Eastern Daylight Time) to update the financial community on points of interest that affect Metiscan and its shareholders. Space is limited on the call-in lines for this national teleconference, therefore in order to participate please call 407-389-5900 and ask for investor relations to make a reservation. If you have a particular question for Mr. Scott, Ms. Frieh or Mr. Hart, please email questions in advance to [email protected].

About Metiscan, Inc.

Metiscan, Inc. (Metiscan), (PINKSHEETS: MTIZ), is the parent company of a portfolio of enterprises with operations in healthcare, healthcare IT, mobile technology and employment services. Metiscan manages all aspects of its subsidiaries and is currently pursuing acquisitions that complement its subsidiaries’ operations. Metiscan’s subsidiaries include FirstView EHR, Inc., Taptopia, Inc., Schuylkill Open MRI, Inc., Shoreline Employment Services, Inc. For more information visit www.metiscan.com

Safe Harbor Statement: Certain of the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Metiscan’s actual results to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Click here to see all recent news from this company

DEERFIELD BEACH, FL–(Marketwire – August 23, 2010) – MedChoice Financial, a national medical financial company, announces M100, a flexible and innovative payment program and accounts receivable management tool to support healthcare practices. Dental, cosmetic, laser hair removal/restoration, chiropractic and medical practitioners are now able to manage their accounts receivables (payments from patients) using a fast and easy to use online patient payment program that MedChoice Financial developed to increase efficiency and facilitate automated collections.

Medical practices now can enroll their patients in the M100 program — enabling them to treat patients that may lack the credit to borrow but have the cash to make payments. Practices can substantially increase the amount of treatments completed and grow their monthly accounts receivable base.

M100 enables medical practices to treat more patients by lowering administrative costs, expediting cash flow and delivering a method to quickly and easily collect receivables. MedChoice Financial takes away the burden that practices have from collecting receivables from patients. Once patients are enrolled in M100, MedChoice Financial will take on the responsibility to electronically charge patients monthly for the amount due and will automatically transfer the money directly to the practices’ financial accounts.

“What makes M100 so innovative is that after patients make nine consecutive payments, the M100 program ensures that practices can recoup up to 90% of any outstanding amount due,” said Valerie Harding, MedChoice Financial’s spokesperson. “Medical practitioners can really leverage the M100 and achieve an effective payment program that helps grow their business, serve more patients, reduces costs and automates patient financing.”

M100 can help a practice in the following ways:

• Enables practices to provide care for patients whose credit was previously an obstacle.
• Provides the flexibility to create customized payment programs for patients based on MedChoice Financial’s recommendations.
• Offers patients a very popular automatic bill payment option.
• Tracks monthly payments and eliminates patients’ disputes as transaction processing is automatic.
• Delivers an easy Web-portal tracking system to manage all inbound receivables.

About MedChoice Financial

MedChoice Financial, headquartered in Deerfield Beach, FL, is a national medical financial institution that services the medical community (medical, dental, cosmetic, chiropractic) and its patients with flexible, convenient financing solutions. Dedicated foremost to superior customer service, MedChoice Financial has become one of the largest and fastest growing elective medical financing companies in the nation. For more information, visit www.medchoicefinancial.com

Click here to see all recent news from this company

TEMPE, AZ–(Marketwire – August 23, 2010) –  New treatments for pain and healing are emerging in alternative medicine. One is the use of low-level lasers to support and encourage patients.

According to Alexandra K. Schnee, D.C., “Cold-Laser Therapy or Low Level Laser Therapy (LLLT) is a treatment that utilizes specific wavelengths of light to interact with tissue and is thought to help accelerate the healing process. It can be used on patients who suffer from a variety of acute and chronic conditions in order to help eliminate pain, swelling, reduce spasms and increase functionality.”

Craig Amrine, a Phoenix area acupuncturist, is a leading authority on cold-laser therapy. “Cold-laser therapy is a non-invasive procedure. Many patients want to try this before resorting to more severe traditional treatments, such as surgery,” states Amrine.

A laser is a device that produces non-ionizing coherent in visible or near visible wavelengths. At certain wavelengths, the light energy passes through the layers of skin and reaches the target area, where it is absorbed and interacts with the light sensitive elements in the cell. This process can be compared to photosynthesis in plants in which sunlight is absorbed by plants, which is then converted to usable energy so that the plant can grow.

The light energy initiates a series of events in the cell that is theorized to normalize damaged or injured tissue. In addition, a reduction in pain, inflammation, edema and an overall reduction in healing time by increasing intracellular metabolism results.

Craig Amrine is a licensed acupuncturist in the state of Arizona (L.Ac.) and is a nationally board certified Diplomat in Acupuncture. He has embraced cold-laser therapy as a part of his acupuncture practice. “I have found cold-laser therapy to be effective for my patients in a variety of areas,” claims Amrine. He continues, “This treatment has worked very well in reducing or eliminating neck, back and joint pain. By stimulating and encouraging the body to heal itself, I consider cold-laser therapy as an important technique to help my patients.”

While still a relatively new treatment option, information is incomplete about its optimal use. However, cold-laser therapy is considered a viable treatment option for those seeking an alternative to invasive treatment. Cold laser therapy is yet another method in the set of tools to help assist in pain relief and accelerate the repair of damaged tissue.

For additional information see: www.hiddenrhythmacupuncture.com.

Click here to see all recent news from this company

NIAGARA FALLS, ONTARIO–(Marketwire – Aug. 22, 2010) – Canadian Doctors for Medicare –

Schedule of Canadian Doctors for Medicare Media Opportunities

Sunday, August 22^nd 1-2:15 p.m., GC chambers (3rd floor, Room ABC)
Media Availability: CMA Education session: There is more to quality than access
Dr. Danielle Martin – Chair, Canadian Doctors for Medicare

Sunday, August 22^nd 2:30-3:45 p.m., GC chambers (3rd floor, Room ABC)
Media Availability: CMA Education session, Health Care Transformation: Will it achieve sustainability?
Dr. Danielle Martin – Chair, Canadian Doctors for Medicare

Monday August 23^rd, 12:30 p.m., Rainbow Salon (10th floor) Crowne Plaza Niagara Falls – Fallsview
Media conference: Release of CDM’s paper on Health Care Transformation
Dr. Danielle Martin – Chair, Canadian Doctors for Medicare
Dr. Robert Woollard – Vice-Chair, Canadian Doctors for Medicare

Tuesday August 24^th, 11:30 a.m., Rainbow Salon (10th floor) Crowne Plaza Niagara Falls – Fallsview
Media conference: Release of CDM’s paper on Sustainability
Dr. Danielle Martin – Chair, Canadian Doctors for Medicare
Dr. Robert Woollard – Vice-Chair, Canadian Doctors for Medicare

Wednesday August 25^th, 12:30 p.m., GC Chambers
Media Availability: Comments on Inaugural Address by Dr. Jeff Turnbull
Dr. Robert Woollard – Vice-Chair, Canadian Doctors for Medicare

Canadian Doctors for Medicare (www.canadiandoctorsformedicare.ca)

Canadian Doctors for Medicare (CDM) represents nearly 2,000 members who share a commitment to the values and principles of Medicare. CDM members recognize the challenges our health care system currently faces, but have consistently proposed resolving those challenges with solutions that respect the principle of access to health care based on need, not ability to pay. CDM spokespersons will be available throughout the Canadian Medical Association General Council.

CONCORD, ONTARIO–(Marketwire – Aug. 20, 2010) – Futuremed Healthcare Income Fund (TSX:FMD.UN) today announced the monthly cash distribution for August 2010 has been set at $0.0771 per unit, or $0.925 per unit on an annualized basis.

The distribution will be paid on September 15^th, 2010, to unit holders of record as at August 31^st, 2010.

Futuremed is Canada’s leading value-added distributor of consumable nursing home supplies and specialized furniture and equipment to the growing long-term care facilities sector.

CONCORD, ONTARIO–(Marketwire – Aug. 20, 2010) – Futuremed Healthcare Income Fund (TSX:FMD.UN) today announced the monthly cash distribution for August 2010 has been set at $0.0771 per unit, or $0.925 per unit on an annualized basis.

The distribution will be paid on September 15^th, 2010, to unit holders of record as at August 31^st, 2010.

Futuremed is Canada’s leading value-added distributor of consumable nursing home supplies and specialized furniture and equipment to the growing long-term care facilities sector.

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MUNDELEIN, IL–(Marketwire – August 20, 2010) –  Medline Industries, Inc., the company that produced the original Pink Glove Dance, is looking for breast cancer survivors in the New York City and surrounding areas who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating more than 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves. Medline, based in Mundelein, Ill., is the largest privately held manufacturer and distributor of healthcare supplies in the country.

When and where will it be?
Filming will take place Saturday, August 28 at 10:00 a.m. at The Broadway Plaza in Times Square between 42nd and 43rd streets.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country inquired about participating in the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

ALEXANDRIA, VA–(Marketwire – August 20, 2010) – All people with type 1 diabetes, and some with type 2, need to inject or pump insulin into their bodies to survive. Figuring out how much insulin is necessary requires frequent monitoring and can be difficult, even risky. According to Diabetes Forecast, the consumer magazine of the American Diabetes Association, one of the most hopeful trends in diabetes research is the quest to develop an artificial pancreas, a device that could make the lives of people with diabetes safer, healthier and easier — possibly within the next few years.

Despite its name, the artificial pancreas would not replace the entire biological organ. Instead, its goal is to mimic the pancreatic beta cells, which are destroyed by a malfunctioning immune system in type 1 diabetes or have stopped producing adequate insulin supply in type 2 diabetes. The artificial pancreas would consist of three components; the first two, an insulin pump and a continuous glucose monitor (CGM), are already used by many people with diabetes. It’s the third piece that acts like a glue between the two systems: an algorithm that will turn data from the CGM into instructions for the insulin pump. “Closing the loop” with an algorithm may allow for an automated system of insulin dosing, allowing the person wearing the device to spend less time on daily diabetes management.

So if we already have insulin pumps and CGMs and we can do some math, why isn’t the artificial pancreas already in place? The main reason is the math itself — and its ability to contribute to safety. While some versions of the algorithm are being developed based on decades of diabetes research and even account for the imperfections of mechanical systems, like delays in CGM measurements or insulin delivery, the line between the ideal blood glucose range and a dangerously low level is very narrow. In fact, Aaron Kowalski, PhD, who oversees the Artificial Pancreas Project at the Juvenile Diabetes Research Foundation, tells Diabetes Forecast that the ideal target for glucose levels is “right next to hypoglycemia, so there’s very little buffer.”

As the artificial pancreas concept evolves, it has taken research into new directions, including shut-off mechanisms for insulin pumps when glucose levels drop too low, pumps that deliver a second hormone in addition to insulin that would raise blood glucose, faster-acting insulins that could make the automated artificial pancreas work more effectively, and, of course, several different algorithms with different capabilities based on an individual’s routine. Getting an artificial pancreas approved for market in the United States is going to take a lot of research — but scientists are closer than they’ve ever been before. 

The artificial pancreas would not be a cure for diabetes. But it has tremendous potential to improve and save lives. And, perhaps, the best part? “An artificial pancreas is there all the time,” says Boris Kovatchev, PhD, who developed one of the algorithms for a U.S. study. “It can make decisions while a person sleeps.” In a not too distant future, people with diabetes may finally be able to rest easy.

The September issue of Diabetes Forecast also reports on how health care reform will affect people with diabetes and their families, including what to expect, and when. By the time the new law has fully taken effect, diabetes should no longer keep people from getting and keeping adequate health insurance coverage.

This issue also offers:

• Eyes on the Prize: Prevention is crucial in combating retinopathy
• Diabetes and Dementia: Does type 2 care also bolster brain function?
• Pump Up the Volume: How to eat more but lose weight

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

ALEXANDRIA, VA–(Marketwire – August 20, 2010) – All people with type 1 diabetes, and some with type 2, need to inject or pump insulin into their bodies to survive. Figuring out how much insulin is necessary requires frequent monitoring and can be difficult, even risky. According to Diabetes Forecast, the consumer magazine of the American Diabetes Association, one of the most hopeful trends in diabetes research is the quest to develop an artificial pancreas, a device that could make the lives of people with diabetes safer, healthier and easier — possibly within the next few years.

Despite its name, the artificial pancreas would not replace the entire biological organ. Instead, its goal is to mimic the pancreatic beta cells, which are destroyed by a malfunctioning immune system in type 1 diabetes or have stopped producing adequate insulin supply in type 2 diabetes. The artificial pancreas would consist of three components; the first two, an insulin pump and a continuous glucose monitor (CGM), are already used by many people with diabetes. It’s the third piece that acts like a glue between the two systems: an algorithm that will turn data from the CGM into instructions for the insulin pump. “Closing the loop” with an algorithm may allow for an automated system of insulin dosing, allowing the person wearing the device to spend less time on daily diabetes management.

So if we already have insulin pumps and CGMs and we can do some math, why isn’t the artificial pancreas already in place? The main reason is the math itself — and its ability to contribute to safety. While some versions of the algorithm are being developed based on decades of diabetes research and even account for the imperfections of mechanical systems, like delays in CGM measurements or insulin delivery, the line between the ideal blood glucose range and a dangerously low level is very narrow. In fact, Aaron Kowalski, PhD, who oversees the Artificial Pancreas Project at the Juvenile Diabetes Research Foundation, tells Diabetes Forecast that the ideal target for glucose levels is “right next to hypoglycemia, so there’s very little buffer.”

As the artificial pancreas concept evolves, it has taken research into new directions, including shut-off mechanisms for insulin pumps when glucose levels drop too low, pumps that deliver a second hormone in addition to insulin that would raise blood glucose, faster-acting insulins that could make the automated artificial pancreas work more effectively, and, of course, several different algorithms with different capabilities based on an individual’s routine. Getting an artificial pancreas approved for market in the United States is going to take a lot of research — but scientists are closer than they’ve ever been before. 

The artificial pancreas would not be a cure for diabetes. But it has tremendous potential to improve and save lives. And, perhaps, the best part? “An artificial pancreas is there all the time,” says Boris Kovatchev, PhD, who developed one of the algorithms for a U.S. study. “It can make decisions while a person sleeps.” In a not too distant future, people with diabetes may finally be able to rest easy.

The September issue of Diabetes Forecast also reports on how health care reform will affect people with diabetes and their families, including what to expect, and when. By the time the new law has fully taken effect, diabetes should no longer keep people from getting and keeping adequate health insurance coverage.

This issue also offers:

• Eyes on the Prize: Prevention is crucial in combating retinopathy
• Diabetes and Dementia: Does type 2 care also bolster brain function?
• Pump Up the Volume: How to eat more but lose weight

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration, and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

NEW YORK, NY–(Marketwire – August 20, 2010) –  The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.

Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment. 

While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:

• minimal invasiveness,
• rapid imaging processing time,
• low imaging cost,
• low radiation dose, and
• optimal resolution and contrast.

“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”

The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.

Kalorama Information’s report, “Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging),” contains more information on market forecasts, company profiles, and trends in the molecular imaging market. The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79480&productid=2613825.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

NEW YORK, NY–(Marketwire – August 20, 2010) –  The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.

Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment. 

While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:

• minimal invasiveness,
• rapid imaging processing time,
• low imaging cost,
• low radiation dose, and
• optimal resolution and contrast.

“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”

The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.

Kalorama Information’s report, “Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging),” contains more information on market forecasts, company profiles, and trends in the molecular imaging market. The report is available at:
http://www.kaloramainformation.com/redirect.asp?progid=79480&productid=2613825.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

CLIFTON, NJ–(Marketwire – August 20, 2010) – Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a global leader in perimeter security systems, today announced receipt of orders totaling $1.1 million for security upgrades at several U.S. Air Force bases and nuclear power stations to meet updated force protection and NRC requirements. In addition, proposals have been submitted for other U.S. Air Force base and nuclear power station upgrades scheduled for fiscal 2011 and 2012.

“These security upgrades have been in the planning stage since 2008 following the terror attacks against our domestic assets in 2001. All branches of government including the nuclear facilities are upgrading and hardening our facilities at an accelerated pace. The NRC has always been one step ahead of potential terrorist threats, and the Department of Defense has increased its efforts in hardening its facilities as well,” commented Arthur Barchenko, President and CEO of ECSI. “Our business is about assisting in the development of security solutions to prevent infiltration of high-value assets and to guard against potential terrorist penetration. We are very proud to be part of this on-going security and anti-terrorism process to help protect the nation’s sensitive and high-visibility sites.” 

These security upgrades include the design and installation of multi-layer security systems including ECSI’s Infrared Perimeter Intrusion Detection (IPID®) system, Fiber Optic Intelligence Detection System (FOIDS®), Intelligent Video Motion Detection (IVMD®) and infrared pan-tilt-zoom camera technology.

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high-profile, high-threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, receipt and timing of collections from purchase orders, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

CLIFTON, NJ–(Marketwire – August 20, 2010) – Electronic Control Security, Inc. (OTCBB: EKCS) (ECSI), a global leader in perimeter security systems, today announced receipt of orders totaling $1.1 million for security upgrades at several U.S. Air Force bases and nuclear power stations to meet updated force protection and NRC requirements. In addition, proposals have been submitted for other U.S. Air Force base and nuclear power station upgrades scheduled for fiscal 2011 and 2012.

“These security upgrades have been in the planning stage since 2008 following the terror attacks against our domestic assets in 2001. All branches of government including the nuclear facilities are upgrading and hardening our facilities at an accelerated pace. The NRC has always been one step ahead of potential terrorist threats, and the Department of Defense has increased its efforts in hardening its facilities as well,” commented Arthur Barchenko, President and CEO of ECSI. “Our business is about assisting in the development of security solutions to prevent infiltration of high-value assets and to guard against potential terrorist penetration. We are very proud to be part of this on-going security and anti-terrorism process to help protect the nation’s sensitive and high-visibility sites.” 

These security upgrades include the design and installation of multi-layer security systems including ECSI’s Infrared Perimeter Intrusion Detection (IPID®) system, Fiber Optic Intelligence Detection System (FOIDS®), Intelligent Video Motion Detection (IVMD®) and infrared pan-tilt-zoom camera technology.

About ECSI
ECSI is a global leader in perimeter security and a quality provider to the Department of Defense, Department of Energy, nuclear power stations, and other large commercial-industrial complexes. The Company designs, manufactures and markets physical electronic security systems for high-profile, high-threat environments utilizing risk assessment and analysis to determine and address the security needs of its customers. Teaming agreements with major system integrators enable ECSI to support the installation and aftermarket of its products in the U.S. and overseas. ECSI is located at 790 Bloomfield Avenue, Bldg. C-1, Clifton, NJ 07012. Tel: 973-574-8555; Fax: 973-574-8562. For more information on ECSI and its customers, please visit http://www.ecsiinternational.com.

ECSI INTERNATIONAL, INC. SAFE HARBOR STATEMENT: This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to changes in economic conditions generally and in our industry specifically, changes in security technology, receipt and timing of collections from purchase orders, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, changes in our operating strategy or development plans, sufficiency of cash reserves and the risks and uncertainties discussed under the heading “RISK FACTORS” in Item 1 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 20, 2010) – www.wallstreetequityresearch.com gives shareholders valuable insight on REIT – healthcare facilities stocks Nationwide Health Properties Inc. (NYSE: NHP) and HCP Inc. (NYSE: HCP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Investors in the REIT healthcare facility sector are hoping that an aging population of baby boomers and recent healthcare reform will translate to solid bottom lines for companies in the sector. Recent increases in occupancy at senior care facilities are reflective of a population drifting into old age.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports REIT – healthcare facilities industry; traders looking for analyst opinions on Nationwide Health Properties Inc., HCP Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

While interest expenses have put a damper on some companies’ earnings, the sector remains positive about the future as the population continues to age and the number of senior care facilities remains comparatively low. Companies are looking to partnerships and mergers to acquire more real estate, including medical office buildings and nursing care projects.

The increased buying activity, especially in medical office buildings, is due in part to the security of the investment. Generally speaking, medical office buildings provide positive returns over long periods of time. This coupled with the potential influx of customers has made medical office buildings attractive to many REIT healthcare companies. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the REIT – healthcare facilities industry in today’s economic environment.

Early this month, Nationwide Health Properties Inc. posted its financial results with revenue surging 13% whilst HCP Inc. saw its revenue increase to $303 million. Traders can have complimentary access to today’s complete research reports on HCP Inc. and Nationwide Health Properties Inc. by signing up at http://wallstreetequityresearch.com/August202010HCPInc.(HCP)200810.php or http://wallstreetequityresearch.com/August202010NationwideHealthPropertiesInc.(NHP)200810.php. 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

JOHANNESBURG, SOUTH AFRICA–(Marketwire – August 20, 2010) – www.wallstreetequityresearch.com gives shareholders valuable insight on REIT – healthcare facilities stocks Nationwide Health Properties Inc. (NYSE: NHP) and HCP Inc. (NYSE: HCP). Sign up today at www.wallstreetequityresearch.com to receive free research reports on these equities.

Investors in the REIT healthcare facility sector are hoping that an aging population of baby boomers and recent healthcare reform will translate to solid bottom lines for companies in the sector. Recent increases in occupancy at senior care facilities are reflective of a population drifting into old age.

www.wallstreetequityresearch.com is a specialized website where investors can have specific access to free reports REIT – healthcare facilities industry; traders looking for analyst opinions on Nationwide Health Properties Inc., HCP Inc. and other companies in this industry are welcomed to sign up for a free one year membership at http://www.wallstreetequityresearch.com/.

While interest expenses have put a damper on some companies’ earnings, the sector remains positive about the future as the population continues to age and the number of senior care facilities remains comparatively low. Companies are looking to partnerships and mergers to acquire more real estate, including medical office buildings and nursing care projects.

The increased buying activity, especially in medical office buildings, is due in part to the security of the investment. Generally speaking, medical office buildings provide positive returns over long periods of time. This coupled with the potential influx of customers has made medical office buildings attractive to many REIT healthcare companies. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting the REIT – healthcare facilities industry in today’s economic environment.

Early this month, Nationwide Health Properties Inc. posted its financial results with revenue surging 13% whilst HCP Inc. saw its revenue increase to $303 million. Traders can have complimentary access to today’s complete research reports on HCP Inc. and Nationwide Health Properties Inc. by signing up at http://wallstreetequityresearch.com/August202010HCPInc.(HCP)200810.php or http://wallstreetequityresearch.com/August202010NationwideHealthPropertiesInc.(NHP)200810.php. 

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

SUN VALLEY, CA–(Marketwire – August 20, 2010) –  XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, received confirmation that the Delaware Chancery Court has scheduled a mediation of the lawsuit that XTend commenced against U&I Bio-Tech Korea, U&I Bio-Tech California, Mr. Sam Lee, and Mr. Eric Shin. Through the litigation, XTend seeks to compel the defendants to perform their obligations under an Asset Purchase Agreement that the parties signed last December, including assigning all of the intellectual property associated with the BioHarp technology to XTend. The mediation proceeding is scheduled for September 30, 2010 at 9:30 am ET before the Honorable Sam Glasscock, III, Master in Chancery.

Mr. Paul D. Lisenby, the CEO of XTend, stated, “XTend Medical has secured a date from the Delaware Chancery Court for mediation between XTend and Sam Lee and the other defendants. It is our intention to present the facts of this case to Master Glasscock and to rely on his wisdom and expertise in complex business matters to assist the parties in resolving the case. The delays and disruption that the defendants have imposed on the company and its shareholders will hopefully finally come to an end through the mediation process. XTend feels very confident in the merits of its case against the defendants. Nevertheless, we look forward to putting this dispute behind us and moving forward with the development of the BioHarp.”

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. For further information, please contact the company at [email protected] or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

SUN VALLEY, CA–(Marketwire – August 20, 2010) –  XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, received confirmation that the Delaware Chancery Court has scheduled a mediation of the lawsuit that XTend commenced against U&I Bio-Tech Korea, U&I Bio-Tech California, Mr. Sam Lee, and Mr. Eric Shin. Through the litigation, XTend seeks to compel the defendants to perform their obligations under an Asset Purchase Agreement that the parties signed last December, including assigning all of the intellectual property associated with the BioHarp technology to XTend. The mediation proceeding is scheduled for September 30, 2010 at 9:30 am ET before the Honorable Sam Glasscock, III, Master in Chancery.

Mr. Paul D. Lisenby, the CEO of XTend, stated, “XTend Medical has secured a date from the Delaware Chancery Court for mediation between XTend and Sam Lee and the other defendants. It is our intention to present the facts of this case to Master Glasscock and to rely on his wisdom and expertise in complex business matters to assist the parties in resolving the case. The delays and disruption that the defendants have imposed on the company and its shareholders will hopefully finally come to an end through the mediation process. XTend feels very confident in the merits of its case against the defendants. Nevertheless, we look forward to putting this dispute behind us and moving forward with the development of the BioHarp.”

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. For further information, please contact the company at [email protected] or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

FORT LAUDERDALE, FL–(Marketwire – August 20, 2010) –  For 13 years, God’s Little Acres (GLA), a non-profit organization, has provided free recreational opportunities for terminally ill and developmentally disabled children. Surviving solely on donations and volunteer support, GLA faces the prospect of shutting down its five-acre ranch in Coconut Creek, FL.

Two weeks ago, GLA was issued a notice from the Bank of America stating foreclosure proceedings against their mortgage were in process.

“I wondered what on earth are we going to do,” Joan Nast, GLA co-founder said. “We have events scheduled and children to help — not to mention eight horses, one Emu and a flock of trained chickens to find a new home for.”

Like many other organizations, GLA’s financial hardships began when GLA’s other co-founder, Bob Nast, could no longer find work as a general contractor. Along with Bob, regular donors and financial backers of GLA were also affected by economic conditions. Without donations, GLA found itself unable to pay the mortgage on their property.

GLA turned to American Residential Law Group (ARLG), a law firm specializing in loan modification assistance and service, to help them regain control on their financial situation. ARLG sent senior attorney, Joel Jacobi, to plead GLA’s case. After demonstrating the humanitarian efforts undertaken by GLA over the years, the judge granted GLA another six months to complete their loan modification.

“[ARLG] is a wonderful firm; honest and rooted in integrity and extreme efficiency,” Joan said. “We aren’t the norm in terms of companies that ask for and are granted home loan modifications, and ARLG has understood that from the beginning.”

This extension will enable GLA to finish their loan modification and keep the ranch activities available for the children and their families. Even though this recent development is good news for GLA, they are still in need of donations and grant money. Joan hopes that one day she will be able to build an indoor facility to accommodate the children who are sensitive to outdoor conditions, but in the mean time, she is focusing on saving the ranch.

“They [ARLG] have used every resource available to help us keep our charity running and we are grateful,” Joan said. “God will send us [financial] backers to get this mortgage paid off.”

If you are interested in donating to God’s Little Acres, please visit their website at www.godslittleacres.org.

About God’s Little Acres: God’s Little Acres is a 501(c)(3) non-profit, multi-cultural, non-religious Florida licensed charity that provides safe and controlled recreational opportunities for terminally ill and developmentally disabled children between the ages of 2 and 11 with their families. The five-acre ranch is located in Coconut Creek, Florida; it serves as an escape for seriously ill children from their typical hospital surroundings. The childrens’ diagnosis include cancer, leukemia, AIDS, cerebral palsy, autism, down syndrome, multiple sclerosis, muscular dystrophy, cystic fibrosis and many other afflictions. 

About American Residential Law Group: American Residential Law Group is a law firm that strives to provide the community with legal assistance and all the benefits to which consumers are entitled under the law. With a considerable background in all areas of consumer advocacy, American Residential Law Group remains dedicated to providing integrity and excellence for their clients and increasing their quality of life. To learn more about home mortgage modifications and how American Residential Law Group can be of assistance to you, visit them at http://www.ARLGNow.com.